Cryoport and cell and gene therapy catapult announce strategic collaboration at stevenage manufacturing innovation centre for advancement of cell and gene therapies

Partnership establishes cryoport systems' first u.k. logistics center to support future expansion and provide end-to-end supply chain solutions for advanced therapy manufacturers nashville, tenn. and stevenage, united kingdom , oct. 10, 2023 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and the cell and gene therapy catapult ("cgt catapult"), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.
CYRX Ratings Summary
CYRX Quant Ranking